News ReleasePremier's OfficeSeptember 16, 2026

Sanofi opens $925M vaccine plant in Toronto, creating 300 skilled jobs

The 263,000 sq ft Charles Best facility at Connaught Campus will make Fluzone High‑Dose for adults 65+, backed by a $55M provincial investment to boost domestic capacity.

Summary

What happened

  • Sanofi and the provincial government opened the Charles Best building, a new 263,000 sq ft vaccine manufacturing facility at the Connaught Campus in North York.

What it will do

  • Manufacture, formulate, fill and package Sanofi’s Fluzone High‑Dose influenza vaccine for adults 65+.
  • Serve as a central hub to strengthen Ontario’s domestic vaccine manufacturing and pandemic response capacity.

By the numbers

  • Facility cost: $925 million.
  • Size: 263,000 square feet.
  • Jobs: 300 new positions described as "good‑paying."
  • Provincial support: $55 million investment.
  • Sanofi’s total announced investment across recent Ontario projects now exceeds $2 billion, with 550+ new jobs across three projects.

Why it matters

  • Expands local production of an age‑specific influenza vaccine, which affects seniors and public health supply chains.
  • Adds manufacturing capacity and skilled jobs in Toronto’s life sciences sector.

Context from the release

  • The project was first announced in 2021 and builds on Sanofi’s existing R&D, manufacturing, clinical and commercial operations in the region.
  • The release links the project to Ontario’s broader life sciences strategy and recent metrics about the sector’s size and workforce.

Related links

Source: Ontario Newsroom

Official release